长期奥西洛司他治疗库欣病期间夜间唾液皮质醇和尿游离皮质醇正常化后临床结局改善

Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol

作者信息John Newell-Price, Maria Fleseriu, Rosario Pivonello, Richard A Feelders, Mônica R Gadelha, André Lacroix, Przemysław Witek, Anthony P Heaney, Andrea Piacentini, Alberto M Pedroncelli, Beverly M K Biller
PMID39610378
发布时间2024-11-12
DOI10.1210/jendso/bvae201

实验完整度

中

该分析为两项III期试验(LINC 3和LINC 4)的汇总数据分析,包含前瞻性干预研究的数据,但未涉及新实验干预,主要基于已有临床试验数据的二次分析。

主要模型

库欣病患者

重点核对

奥西洛司他初始剂量2 mg每日两次,逐步滴定至30 mg每日两次 皮质醇控制状态分组(LNSC和mUFC均控制、仅mUFC控制、仅LNSC控制、均未控制) 检测时间点:基线、第48周、第72周 LNSC正常范围≤2.5 nmol/L,mUFC正常范围11-138 nmol/24小时

摘要

Purpose: To assess whether simultaneous normalization of late-night salivary cortisol (LNSC) and mean urinary free cortisol (mUFC) in patients with Cushing disease treated with osilodrostat is associated with better clinical outcomes than control of mUFC or LNSC alone. Methods: Pooled data from two phase III osilodrostat studies (LINC 3 and LINC 4) were analyzed. Both comprised a 48-week core phase and an optional open-label extension. Changes in cardiovascular/metabolic-related parameters, physical manifestations of hypercortisolism, and quality of life (QoL) were evaluated across the following patient subgroups: both LNSC and mUFC controlled, only mUFC controlled, only LNSC controlled, and neither controlled. Results: Of 160 patients included in the analysis, 85.0% had both LNSC and mUFC uncontrolled at baseline. At week 72, 48.6% of patients had both LNSC and mUFC controlled; these patients generally exhibited greater improvements in cardiovascular/metabolic-related parameters than those with only mUFC controlled or both LNSC and mUFC uncontrolled: systolic/diastolic blood pressure, -7.4%/-4.9%, -6.0%/-5.5%, and 2.3%/0.8%, respectively; fasting plasma glucose, -5.0%, -4.8%, and 1.9%; glycated hemoglobin, -5.1%, -4.8%, and -1.3%. Weight, waist circumference, and body mass index improved with control of LNSC and/or mUFC; physical manifestations of hypercortisolism generally improved regardless of LNSC/mUFC control. Patients with both LNSC and mUFC controlled or only mUFC controlled had the greatest improvement from baseline to week 72 in QoL. Conclusion: In osilodrostat-treated patients with Cushing disease, normalization of LNSC and mUFC led to improvements in long-term outcomes, indicating that treatment should aim for normalization of both parameters for optimal patient outcomes. Clinical trial identifiers: NCT02180217 (LINC 3); NCT02697734 (LINC 4).

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
在奥西洛司他治疗的库欣病患者中,同时实现夜间唾液皮质醇(LNSC)和平均尿游离皮质醇(mUFC)正常化是否比单独控制其中一项带来更好的临床结局?
核心机制
同时控制LNSC和mUFC与更佳的心血管代谢参数和生存质量改善相关,而仅控制mUFC不足以作为最优疾病控制的标志。
主要证据
基于LINC 3和LINC 4两项III期研究的汇总数据,评估心血管代谢参数、身体表现和生存质量在不同皮质醇控制分组中的变化。
研究意义
研究表明,在库欣病患者中,治疗应旨在同时使LNSC和mUFC正常化,以获得最佳长期临床结局,有助于指导个体化治疗策略。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

患者入组与分组

汇总LINC 3和LINC 4研究中接受奥西洛司他治疗的库欣病患者,并根据LNSC和mUFC控制状态进行分组。

纳入来自两项III期研究的患者数据,根据LNSC和mUFC是否控制在正常范围内,将患者分为四组:两者均控制、仅mUFC控制、仅LNSC控制、两者均未控制。

2

临床结局评估

评估不同皮质醇控制状态下,患者心血管代谢参数、身体表现及生存质量从基线到第48周和第72周的变化。

测量血压、空腹血糖、糖化血红蛋白、体重、BMI、腰围、血脂等心血管代谢参数;评估身体表现(如面部潮红、紫纹、锁骨上脂肪垫等)和生存质量(CushingQoL和BDI-II评分)。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

产品清单

实验环节名称品牌货号
高通量液相色谱系统Cohesive Technologies--
串联质谱仪ThermoFinnigan--

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
患者入组
年龄18-75岁,确诊为持续性/复发性库欣病或为新发(非手术候选),晨起血浆ACTH高于正常下限,mUFC >1.5倍正常上限(LINC 3)或 >1.3倍(LINC 4)
阅读提示:见Methods部分患者入组标准
治疗给药
奥西洛司他初始剂量2 mg每日两次,滴定方案为2-5-10-20-30 mg每日两次,最大剂量30 mg每日两次
阅读提示:见Methods部分研究设计
生化评估
LNSC和mUFC采用LC-MS/MS检测,LNSC正常范围≤2.5 nmol/L,mUFC正常范围11-138 nmol/24小时
阅读提示:见Methods部分皮质醇水平检测
结局评估
在基线和第48、72周评估心血管代谢参数、身体表现和生存质量
阅读提示:见Methods部分评估指标